Intra-Cellular Therapies, Inc. clinical trial pipeline
Data updated daily from ClinicalTrials.gov, last refresh 2026-11-19
What changed in the last 30 days
4 trials changed in the last 30 days: 0 stopped, 1 with a notable change, 3 with minor changes only.
- Notable: JNJ-99245354 (ITI-1284) as an Adjunctive Treatment · Generalized Anxiety Disorder (GAD) Who Have an Inadequate Response to GAD Treatment Recruitment opened
- Minor: Lumateperone · Irritability Associated With Autism Spectrum Disorder in Pediatric Patients Trial sites expanded: 35 → 39 locations
- Minor: ITI-1284 as an Adjunctive Treatment · Generalized Anxiety Disorder Trial sites expanded: 56 → 59 locations
- Minor: CANDLE · Lumateperone Versus Placebo · Major Depressive Disorder Study completion pushed from Sep 20, 2029 to Oct 23, 2029
- Stopped: terminated, suspended or withdrawn
- Notable: the plan changed
- Minor: routine updates
Active trials by phase
| Phase 2 | 4 | |
| Phase 3 | 8 |
Disease areas by active trials
Anxiety (4) · Depression (3) · Alzheimer's Disease (2) · Bipolar Disorder (2) · Dementia (2) · Schizophrenia (1)
Get alerts when Intra-Cellular Therapies, Inc.'s trials change
Status changes, date slips, and new filings: detected daily, delivered to your inbox.